Collegium director sells 4,500 shares in open trade
Collegium Pharmaceutical director Nancy Lurker reported an open-market sale of Common Stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Collegium Pharmaceutical director Nancy Lurker reported an open-market sale of Common Stock. On May 13, 2026, she sold 4,500 shares at a weighted average price of $35.9691 per share, in multiple trades between $35.55 and $36.50. After this transaction, she directly holds 18,017 shares of Collegium Pharmaceutical common stock.
Insider Trade Summary
Net Seller: 4,500 shares
Net Sell
1 txn
Insider
Lurker Nancy
Role
Director
Sold
4,500 shs ($162K)
Share of Position Sold
20.0%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,500 | $35.9691 | $162K |
Holdings After Transaction:
Common Stock — 18,017 shares (Direct)
Holdings Before and After:
Common Stock, 22,517 to 18,017 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (1)
- F1. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.55 to $36.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 4,500 shares
Weighted average sale price: $35.9691 per share
Post-transaction holdings: 18,017 shares
+1 more
4 metrics
Shares sold
4,500 shares
Open-market sale on May 13, 2026
Weighted average sale price
$35.9691 per share
Common Stock sale on May 13, 2026
Post-transaction holdings
18,017 shares
Direct ownership after the sale
Trade price range
$35.55–$36.50 per share
Prices across multiple sale executions
Key Terms
open-market sale, weighted average price, Form 4, non-derivative
4 terms
open-market sale financial
"the transaction_action field describes the trade as an open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
non-derivative financial
"transaction_type is listed as non-derivative for this Common Stock sale"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Nancy Lurker report at Collegium Pharmaceutical (COLL)?
Director Nancy Lurker reported selling 4,500 shares of Collegium Pharmaceutical common stock. The transaction was an open-market sale, with a weighted average price of $35.9691 per share, and left her holding 18,017 shares directly.
Was Nancy Lurker’s Collegium Pharmaceutical (COLL) trade a market sale or another type of transaction?
The filing identifies Nancy Lurker’s transaction as an open-market sale of Collegium Pharmaceutical common stock. It is coded as a “S” transaction, described as a sale in an open market or private transaction, rather than an option exercise, gift, or tax withholding.
Does the Collegium Pharmaceutical (COLL) insider filing show any option exercises by Nancy Lurker?
No option exercises are reported in this Form 4 for Nancy Lurker. The transaction summary shows zero derivative exercises and indicates only one non-derivative open-market sale of 4,500 common shares, with no derivative positions listed in the derivative summary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
